May SAS-B approvals hit 2026 high as Victoria extends prescribing lead by Adam Sheldon June 3, 2026June 4, 2026 Approvals through the Special Access Scheme reached a 2026 high in May, with Victoria accounting for […]
April SAS-B figures: pastilles hit nearly one-third of approvals by Adam Sheldon May 7, 2026May 7, 2026
Bioxyne lifts FY26 guidance after margin growth in strong first half by Steve Jones February 26, 2026February 26, 2026
TGA offers first clues to where industry can expect to face regulatory reform by Steve Jones February 23, 2026February 25, 2026
Pastilles surge again as SAS-B data shows strong start to 2026 by Steve Jones February 2, 2026February 3, 2026
SAS-B deep dive: approvals climb 26% in 2025 as flower overtakes oil and pastilles surge by Adam Sheldon January 13, 2026January 14, 2026
Bioxyne enters Central American markets with pastille supply deal by Steve Jones December 12, 2025December 12, 2025
Pastilles climb past oil to become second largest SAS-B dosage form by Steve Jones December 2, 2025December 4, 2025
